Repare Therapeutics is a clinical-stage precision oncology company that specializes in developing novel medicines using its proprietary synthetic lethality approach. Their aim is to address the genetic alterations associated with specific tumors and provide targeted therapies. With a focus on precision and enrichment, Repare Therapeutics is advancing a new class of therapies that have the potential to significantly benefit cancer patients.

The company leverages its SNIPRx platform to discover, validate, and build a robust pipeline of synthetic lethality-based therapeutics. Their portfolio of product candidates, developed through clinical trials, targets cancers with a high unmet medical need. Repare Therapeutics has achieved notable milestones, including proof of concept for Lunresertib (RP-6306) in clinic and clinical benefit shown by Camonsertib in advanced solid tumors, as highlighted in a publication in Nature Medicine.

Join their team to make a difference and contribute to their mission of improving cancer treatment through innovative precision oncology solutions